Performance-Based Risk-Sharing Arrangements: An Updated International Review

被引:72
作者
Carlson, Josh J. [1 ]
Chen, Shuxian [1 ]
Garrison, Louis P., Jr. [1 ]
机构
[1] Univ Washington, Pharmaceut Outcomes Res & Policy Program, 1959 NE Pacific St,Box 357630, Seattle, WA 98195 USA
关键词
HEALTH-CARE PAYERS; COVERAGE DECISIONS; PHARMACEUTICALS; MANUFACTURERS; TECHNOLOGIES; AGREEMENTS; TRENDS;
D O I
10.1007/s40273-017-0535-z
中图分类号
F [经济];
学科分类号
02 ;
摘要
Enthusiasm for performance-based risk-sharing arrangements (PBRSAs) continues but at variable pace across countries. Our objective was to identify and characterize publicly available cases and related trends for these arrangements. We performed a review of PBRSAs from 1993 to 2016 using the University of Washington PBRSA Database. Arrangements were categorized according to a previously published taxonomy. Macro-level trends were identified related to the timing of adoption, countries involved, types of arrangements, and disease areas. Our search yielded 437 arrangements. Among these, 183 (41.9%) were categorized as currently active, while 58.1% have expired. Five main types of arrangements have been identified, namely coverage with evidence development (149 cases, 34.1%), performance-linked reimbursement (104 cases, 23.8%), conditional treatment continuation (78 cases, 17.8%), financial or utilization (71 cases, 16.2%), and hybrid schemes with multiple components (35 cases, 8.0%). The pace of adoption varies across countries but has renewed an upward trend after a lull in 2012/2013. Conditions in the USA may be changing toward a more favorable environment of PBRSAs. Interest in PBRSAs remains high, suggesting they are a viable coverage and reimbursement mechanism for a wide range of medical products.
引用
收藏
页码:1063 / 1072
页数:10
相关论文
共 27 条
  • [1] AIFA, 2017, LIST AGG REG PIAN TE
  • [2] Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers
    Carlson J.J.
    Gries K.S.
    Yeung K.
    Sullivan S.D.
    Garrison Jr. L.P.
    [J]. Applied Health Economics and Health Policy, 2014, 12 (3) : 231 - 238
  • [3] Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers
    Carlson, Josh J.
    Sullivan, Sean D.
    Garrison, Louis P.
    Neumann, Peter J.
    Veenstra, David L.
    [J]. HEALTH POLICY, 2010, 96 (03) : 179 - 190
  • [4] Chambers J, 2013, HLTH AFFAIRS BLOG
  • [5] CMS, 2016, MED PROGR B
  • [6] CMS, 2017, CMS COV EV DEV
  • [7] de Pouvourville Gerard, 2006, Eur J Health Econ, V7, P155
  • [8] When do performance-based risk-sharing arrangements make sense?
    Drummond, Michael
    [J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2015, 16 (06) : 569 - 571
  • [9] Sharing Risk between Payer and Provider by Leasing Health Technologies: An Affordable and Effective Reimbursement Strategy for Innovative Technologies?
    Edlin, Richard
    Hall, Peter
    Wallner, Klemens
    McCabe, Christopher
    [J]. VALUE IN HEALTH, 2014, 17 (04) : 438 - 444
  • [10] Espin J., 2011, Review Series on Pharmaceutical Pricing Policies and Interventions - Working Paper 1: External Reference Pricing